Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc

Ewing Sarcoma pipeline constitutes 25+ key companies continuously working towards developing 25+ Ewing Sarcoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ewing Sarcoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ewing Sarcoma Market.

The Ewing Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ewing Sarcoma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Ewing Sarcoma treatment therapies with a considerable amount of success over the years. Ewing Sarcoma Key players such as - Nanovalent Pharmaceuticals, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc., Shanghai Pharmaceuticals Holding, Exelixis, Gradalis, Inc., and others, are developing therapies for the Ewing Sarcoma treatment

*
Ewing Sarcoma Emerging therapies such as - NV-101, OMTX-703, VAL-413, CLR 131, Eribulin mesylate, TK216, Cabozantinib, Vigil EWS, and others are expected to have a significant impact on the Ewing Sarcoma market in the coming years.

*
In July 2025, Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing treatments for challenging, high-impact cancers through GSK-3 inhibition, has announced the completion of the Phase 1 segment of its clinical trial (Actuate-1902). The study evaluated elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus temozolomide, or cyclophosphamide plus topotecan in pediatric patients with relapsed cancers. Encouraging signs of efficacy were observed, especially in treatment-resistant Ewing Sarcoma (EWS), a rare soft tissue and bone tumor. Based on these results, the company plans to move forward with a Phase 2 trial involving children, adolescents, and adults with relapsed/refractory EWS.

*
In November 2024, The FDA awarded rare pediatric disease designation to elraglusib (9-ING-41), an innovative GSK-3 inhibitor, as a potential treatment for Ewing sarcoma. The investigational therapy is currently being assessed in the open-label, multicenter Phase 1/2 Actuate-1902 trial (NCT04239092), which is examining its safety and efficacy in pediatric patients with relapsed or refractory cancers, including Ewing sarcoma and related small round cell sarcomas.

Ewing Sarcoma Overview

Ewing sarcoma is a rare type of cancer that primarily affects the bones or soft tissues. It most commonly occurs in children and young adults, typically between the ages of 10 and 20, but it can also occur in older adults. Ewing sarcoma most often arises in the bones of the pelvis, thighs, upper arms, or chest wall.

Get a Free Sample PDF Report to know more about Ewing Sarcoma Pipeline Assessment-

https://www.delveinsight.com/report-store/ewing-sarcoma-pipeline-insight [https://www.delveinsight.com/report-store/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ewing Sarcoma Pipeline Therapeutics Assessment

*
Ewing Sarcoma Assessment by Product Type

*
Ewing Sarcoma By Stage and Product Type

*
Ewing Sarcoma Assessment by Route of Administration

*
Ewing Sarcoma By Stage and Route of Administration

*
Ewing Sarcoma Assessment by Molecule Type

*
Ewing Sarcoma by Stage and Molecule Type

DelveInsight's Ewing Sarcoma Report covers around 25+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Emerging Ewing Sarcoma Drugs Under Different Phases of Clinical Development Include:

*
NV-101: Nanovalent Pharmaceuticals

*
OMTX-703: Oncomatryx

*
VAL-413: Valent Technologies

*
CLR 131: Cellectar Biosciences

*
Eribulin mesylate: Eisai Inc.

*
TK216: Shanghai Pharmaceuticals Holding

*
Cabozantinib: Exelixis

*
Vigil EWS: Gradalis, Inc.

Download Sample PDF Report to know more about Ewing Sarcoma drugs and therapies [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ewing Sarcoma Pipeline Analysis:

The Ewing Sarcoma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the Ewing Sarcoma treatment with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ewing Sarcoma Treatment.

*
Ewing Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Ewing Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ewing Sarcoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Ewing Sarcoma product details are provided in the report. Download the Ewing Sarcoma pipeline report to learn more about the emerging Ewing Sarcoma therapies [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Ewing Sarcoma Pipeline Market Drivers

*
Rising awareness about Ewing Sarcoma and financial assistance programs

*
Demand for New and Effective Drugs

Ewing Sarcoma Pipeline Market Barriers

*
Lack of approved therapies for Ewing's sarcoma

*
Absence of predictive biomarkers in Ewing's sarcoma

Scope of Ewing Sarcoma Pipeline Drug Insight

*
Coverage: Global

*
Key Ewing Sarcoma Companies: Nanovalent Pharmaceuticals, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc., Shanghai Pharmaceuticals Holding, Exelixis, Gradalis, Inc., and others

*
Key Ewing Sarcoma Therapies: NV-101, OMTX-703, VAL-413, CLR 131, Eribulin mesylate, TK216, Cabozantinib, Vigil EWS, and others

*
Ewing Sarcoma Therapeutic Assessment: Ewing Sarcoma current marketed and Ewing Sarcoma emerging therapies

*
Ewing Sarcoma Market Dynamics: Ewing Sarcoma market drivers and Ewing Sarcoma market barriers

Request for Sample PDF Report for Ewing Sarcoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Ewing Sarcoma Report Introduction

2

Ewing Sarcoma Executive Summary

3

Ewing Sarcoma Overview

4

Ewing Sarcoma- Analytical Perspective In-depth Commercial Assessment

5

Ewing Sarcoma Pipeline Therapeutics

6

Ewing Sarcoma Late Stage Products (Phase II/III)

7

Ewing Sarcoma Mid Stage Products (Phase II)

8

Ewing Sarcoma Early Stage Products (Phase I)

9

Ewing Sarcoma Preclinical Stage Products

10

Ewing Sarcoma Therapeutics Assessment

11

Ewing Sarcoma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Ewing Sarcoma Key Companies

14

Ewing Sarcoma Key Products

15

Ewing Sarcoma Unmet Needs

16

Ewing Sarcoma Market Drivers and Barriers

17

Ewing Sarcoma Future Perspectives and Conclusion

18

Ewing Sarcoma Analyst Views

19

Appendix

20

About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ewing-sarcoma-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-nanovalent-pharma-oncomatryx-valent-technologies-cellectar-biosciences-eisai-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.